Two New Treatments for Gonorrhea; one is available now!

In this episode of the Conversations with CEI, infectious disease specialist Dr. Steven Fine delves into groundbreaking advancements in the treatment of urogenital gonorrhea. The episode highlights the FDA's December 2025 approval of two innovative oral therapies that mark a significant step forward in combating this prevalent sexually transmitted infection.

Dr. Fine discusses the first of these treatments, Zoliflodacin (Nuzolvence), a novel medication specifically developed for urogenital gonorrhea. Administered as a single oral dose, it offers patients a convenient and effective option. The second treatment, Gepotidacin (Blujepa), is a versatile drug initially approved in March 2025 for urinary tract infections (UTIs). Now, it has been authorized for urogenital gonorrhea treatment, requiring two oral doses for optimal efficacy.

Throughout the episode, Dr. Fine provides insights into the clinical trials, mechanisms of action, and potential impact of these therapies on public health. He also emphasizes the importance of addressing antibiotic resistance in gonorrhea and how these new treatments may help mitigate this growing concern.

For more information, listeners can refer to the FDA's official announcement and other resources provided below.

Tune in to this episode to learn more about these exciting developments and their implications for the future of infectious disease treatment. Related Content:

• FDA Approves Two Oral Therapies to Treat Gonorrhea https://www.fda.gov/news-events/press-announcements/fda-approves-two-oral-therapies-treat- gonorrhea
• CEI Clinical Consultation Line 1-866-637-2342 A toll-free service for NYS clinicians offering real-time clinical consultations with specialists on HIV, sexual health, hepatitis C, and drug user health.
• https://ceitraining.org/